Loading stock data…
$0.21-0.01 (-2.60%)
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
Theriva Biologics, Inc. in the Healthcare sector is trading at $0.21 with a market capitalization of $11M. Wall Street consensus targets $2.50 (2 analysts), implying a +1089.9% move over the next 12 months. The stock is currently near its 52-week low of $0.16, remaining 12.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $300,000 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.29M↓ | -$2.13M↓ | -$2.06M↑ | -$4.44M↑ | -$13.13M |
| Net Income | -$3.22M↓ | -$2.04M↓ | -$2.00M↑ | -$4.36M↑ | -$13.06M |
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic...